Hongtai Aplus
Overview
Hongtai Aplus is an investment firm founded in 2014 that focuses on venture capital and fund of fund investments across China, with a focus on information technology, advanced manufacturing, pharmacy & medical care, consumption & education, and new materials.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| UniPat AI | Sep 2026 | Early Funding | Co-investor |
| Accro Bioscience Inc. | Jan 2022 | Series B | Lead |
| KKV | Aug 2020 | Series E | Co-investor |
| Luoji Siwei | Sep 2017 | Series D | Co-investor |
| Shinehigh Innovation | - | Series A | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Hongtai Aplus based?
Hongtai Aplus is headquartered in Beijing, China.
When was Hongtai Aplus founded?
Hongtai Aplus was founded in 2014.
How many portfolio companies does Hongtai Aplus have?
Hongtai Aplus has 5 portfolio companies in Caplight's dataset.
What are some companies in Hongtai Aplus's portfolio?
Recent investments visible on Caplight include UniPat AI, Accro Bioscience Inc., KKV, Luoji Siwei, Shinehigh Innovation.
What was Hongtai Aplus's most recent investment?
Hongtai Aplus's most recent investment on Caplight was in UniPat AI in 2026.
What sectors does Hongtai Aplus focus on?
Hongtai Aplus focuses on Healthcare & Life Sciences, Consumer & Commerce, AI, Data & Cloud Infrastructure, Media, Entertainment & Gaming, Healthcare & Life Sciences, Consumer & Commerce, Consumer & Commerce, Enterprise Software.
What company stages does Hongtai Aplus focus on?
Hongtai Aplus typically invests at the Early stage.
What is Hongtai Aplus's AUM?
Hongtai Aplus's assets under management are estimated between $4.1B and $4.1B.